Based on the high prevalence of increased cholesterol levels and the greater risk of opioid-induced respiratory depression with reduced P-glycoprotein activity, we hypothesize that hyperlipidemia boosts brain nalbuphine uptake and therefore could enhance its pharmacological effects in this patient population. Here, ABCB1 is linked to respiratory depression.